Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCAF1 | Q9Y4B6 | 11/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35212183 | 1.00 | DCAF1 (0.43) | DCAF1CNR2MAPK1AURKACDK2 | |
| SCHEMBL35212462 | 1.00 | DCAF1 (0.43) | DCAF1CNR2MAPK1AURKACDK2 | |
| SCHEMBL35212406 | 0.95 | DCAF1 (0.42) | DCAF1CNR2MAPK1AURKACDK2 | |
| SCHEMBL35212451 | 0.93 | DCAF1 (0.41) | DCAF1CNR2MAPK1AURKACDK2 | |
| SCHEMBL35211915 | 0.93 | DCAF1 (0.41) | DCAF1CNR2MAPK1AURKACDK2 | |
| SCHEMBL30937313 | 0.92 | DCAF1 (0.42) | DCAF1CNR2MAPK1AURKACDK2 | |
| SCHEMBL35211902 | 0.90 | DCAF1 (0.41) | DCAF1CNR2MAPK1AURKACDK2 | |
| SCHEMBL27369934 | 0.87 | DCAF1 (0.48) | DCAF1CNR2MAPK1AURKACDK2 | |
| SCHEMBL30937280 | 0.86 | DCAF1 (0.38) | DCAF1CNR2MAPK1 | |
| SCHEMBL35212171 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | DCAF1 2314/4885CNR2 68/4885MAPK1 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.